Updated clinical and biological information from the two-stage phase II study of imatinib mesylate in subjects with relapsed/refractory neuroblastoma

F. Morandi, L. Amoroso, A. Dondero, R. Castriconi, S. Parodi, R. Luksch, F. Casale, A. Castellano, A. Garaventa, A. Moretta, C. Bottino, M. Ponzoni, M.V. Corrias

Research output: Contribution to journalArticlepeer-review

Cite this